Clinical Trial

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

Study acronym: ReciDOPA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-07; most recent amendment 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT05653635
Lead Sponsor Centre Paul Strauss
Collaborators: Centre Georges François Leclerc
Conditions Glioblastoma
Enrollment 54 participants
Start Date 2026-03-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-04